Active ingredient

Nanophase Announces Successful Litigation Settlement

Retrieved on: 
Jeudi, avril 11, 2024
Sale, Vexatious litigation, Prejudice, Skin, OTCQB, BASF, Partnership, Active ingredient, API, Beauty, Superior court, Pharmaceutical industry

The parties have executed a Settlement Agreement, an amendment to their existing supply contract, and a joint stipulation to dismiss the case with prejudice to be filed in the Superior Court of New Jersey within the next five business days.

Key Points: 
  • The parties have executed a Settlement Agreement, an amendment to their existing supply contract, and a joint stipulation to dismiss the case with prejudice to be filed in the Superior Court of New Jersey within the next five business days.
  • “We are happy to conclude this litigation on positive terms.
  • BASF has been a good partner to Nanophase over the years, and we expect that partnership to continue to bear fruit in the future,” said Nanophase President and Chief Executive Officer, Jess Jankowski.
  • Completion of the settlement allows Nanophase and Solésence to focus on what we do best, while continuing to support our sale of mineral-based Active Pharmaceutical Ingredients (“API”), into a market that recognizes the benefits these solutions bring,” continued Jankowski.

Tequila Zarpado Introduces Añejo Tequila

Retrieved on: 
Jeudi, avril 25, 2024
Wine, Active ingredient, Vanilla, Blue agave, Agave, SRP, Tequila, Cinco de Mayo, Spice, Ageing, Liquor

BOSTON, April 25, 2024 /PRNewswire/ -- Tequila Zarpado, a line of small-batch premium Tequilas, today introduced its latest expression, Zarpado Añejo, hitting shelves just in time for Cinco de Mayo. Handcrafted at a boutique, family-owned distillery in Jalisco, Mexico, the Tequila is aged more than one year in a combination of Bourbon and French Oak casks. The expression retails for less than $40, giving Tequila lovers a true craft Añejo at an everyday price.

Key Points: 
  • The expression retails for less than $40, giving Tequila lovers a true craft Añejo at an everyday price.
  • Crafted by a family-owned distillery in Jalisco, Mexico, Tequila Zarpado Añejo offers craft quality at an everyday price.
  • Like the Blanco and Reposado Tequilas already on the market, Zarpado Añejo is made from 100% mature Blue Agave grown in the Los Valles region of Jalisco.
  • Tequila Zarpado Blanco and Reposado are also available in the same markets with SRP of $26.99 and $29.99 respectively.

Clarivate Acquires Global QMS, Inc., Expanding Life Sciences & Healthcare Segment into New Markets

Retrieved on: 
Mardi, avril 23, 2024
DRG, CLVT, IP, Clarivate, Decision, Health care, ProQuest, Workflow, Medtech, Software as a service, API, Intelligence, Automation, Patient, Acquisition, Active ingredient, Medical device

LONDON, April 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced that it has acquired Global QMS, Inc., known as Global Q, a provider of cloud-based solutions that enable life sciences clients to automate regulatory reporting and compliance management. Financial terms of the transaction were not disclosed. 

Key Points: 
  • Clarivate brings together connected data, deep expertise and intelligence solutions to empower life sciences and healthcare companies to deliver safe, effective and commercially successful treatments to patients faster.
  • The workflow and reporting capabilities of Global Q complement the Clarivate Cortellis Generics Intelligence solution for Active Pharmaceutical Ingredient (API) tracking.
  • The addition of these cloud-based solutions will serve to embed Clarivate into critical client workflows and enable the expansion of Clarivate services into new markets.
  • Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: "Clarivate continues to explore, develop and integrate next-generation workflow automation software that streamlines and digitizes manual workflows.

Clarivate Acquires Global QMS, Inc., Expanding Life Sciences & Healthcare Segment into New Markets

Retrieved on: 
Mardi, avril 23, 2024
DRG, CLVT, IP, Clarivate, Decision, Health care, ProQuest, Workflow, Medtech, Software as a service, API, Intelligence, Automation, Patient, Acquisition, Active ingredient, Medical device

LONDON, April 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced that it has acquired Global QMS, Inc., known as Global Q, a provider of cloud-based solutions that enable life sciences clients to automate regulatory reporting and compliance management. Financial terms of the transaction were not disclosed. 

Key Points: 
  • Clarivate brings together connected data, deep expertise and intelligence solutions to empower life sciences and healthcare companies to deliver safe, effective and commercially successful treatments to patients faster.
  • The workflow and reporting capabilities of Global Q complement the Clarivate Cortellis Generics Intelligence solution for Active Pharmaceutical Ingredient (API) tracking.
  • The addition of these cloud-based solutions will serve to embed Clarivate into critical client workflows and enable the expansion of Clarivate services into new markets.
  • Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: "Clarivate continues to explore, develop and integrate next-generation workflow automation software that streamlines and digitizes manual workflows.

ADAMA Launches New Cereal Fungicide Avastel® for Superior Disease Control and Long-lasting Protection

Retrieved on: 
Lundi, avril 22, 2024
Active ingredient, TEL, Weather, Wheat, Triticale, Farmer, SDHI, Disease, Triazole, Pressure, DMI, Agriculture

Avastel® has powerful curative and long-term preventive effects against disease, resulting in a stronger flag leaf which is crucial for maximizing yields.

Key Points: 
  • Avastel® has powerful curative and long-term preventive effects against disease, resulting in a stronger flag leaf which is crucial for maximizing yields.
  • "At ADAMA, we invested in developing Avastel®, a breakthrough fungicide that contains two best-in-class Active Ingredients as well as our innovative Formulation Technology.
  • Avastel® is a broad label fungicide that is suitable for use in crops such as wheat, barley, rye, and triticale.
  • It is part of ADAMA's new European cereal fungicide portfolio which began rolling out in 2023.

Adam Grant Headlines VOICES by Staffbase - 2024's Largest Internal Communications Event

Retrieved on: 
Mercredi, avril 17, 2024
Narrative, System, DHL, Book, Active ingredient, Motivation, Trust, HGTV, Business, TED (conference), Culture, Cultural center, SVP, Inclusive, Campaign manager, Communication, Workforce, Arnold Bakker, Southwest Airlines, Internal communications, Management

NEW YORK, April 17, 2024 /PRNewswire/ -- Staffbase, a leading employee communications cloud provider, today announced its roster of speakers and agenda for VOICES 2024. VOICES, the leading event for the internal communications community, will take place virtually on May 16, 2024, from 11:00 a.m. ET – 6:00 p.m. ET. This year's event will offer communications teams across North America access to industry veterans and thought leaders. Combined with a stellar list of speakers who will discuss culture, change management, employee engagement & motivation, and leadership communications, VOICES will be the premier event of the year for communicators.

Key Points: 
  • VOICES, the leading event for the internal communications community, will take place virtually on May 16, 2024, from 11:00 a.m.
  • This year's event will offer communications teams across North America access to industry veterans and thought leaders.
  • This year's free event offers communications teams across North America access to industry veterans and thought leaders.
  • We're convening some of the most brilliant minds in organizational psychology, business communications, and strategy with only one goal: To empower and enable internal communications experts."

BONEFISH GRILL RAISES ITS BRUNCH GAME WITH EXPANDED MENU, EXTRA DAY

Retrieved on: 
Mardi, avril 16, 2024
Creole, Grand Marnier, Cheese, Bread, Collection, Eggs Benedict, Breakfast, Fontina, Active ingredient

TAMPA, Fla., April 16, 2024 /PRNewswire/ -- Guests have two more reasons to love brunch at Bonefish Grill, which has revamped and reintroduced several popular menu items and made the event a two-day affair by adding Saturdays to the experience. The even more enticing combination of top-tier service, innovative dishes and expertly crafted cocktails makes this the perfect place for brunch besties to relax and connect any day of the weekend.

Key Points: 
  • Delicious new choices, returning showstoppers, uniquely crafted cocktails and more – so much more, the restaurant has added Saturdays so guests can experience it all.
  • TAMPA, Fla., April 16, 2024 /PRNewswire/ -- Guests have two more reasons to love brunch at Bonefish Grill, which has revamped and reintroduced several popular menu items and made the event a two-day affair by adding Saturdays to the experience.
  • The even more enticing combination of top-tier service, innovative dishes and expertly crafted cocktails makes this the perfect place for brunch besties to relax and connect any day of the weekend.
  • "We're excited to bring our guests their favorite Bonefish brunch offerings, now reimagined with innovative twists and an additional day to enjoy them," said Mark Graff, President of Bonefish Grill."

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Retrieved on: 
Lundi, avril 8, 2024
EGFR, Patient, Anaplastic lymphoma kinase, Research, Alectinib, Active ingredient, Lung cancer, AACR, AstraZeneca, ALK, Vaccine

Fort Lee, NJ, April 08, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) today recapped poster highlights from the 2024 American Association for Cancer Research (AACR) conference demonstrating highly synergistic antiproliferative activity in epidermal growth factor receptor (EGFR)-resistant non-small cell lung cancer (NSCLC) cells of NXP900 in combination with osimertinib, the active ingredient in TagrissoTM, an EGFR inhibitor approved for the treatment of NSCLC. The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.

Key Points: 
  • The data reported, which confirms data previously published by the research team at Astra Zeneca, demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone.
  • In addition, NXP900 demonstrated potent, single agent, antiproliferative activity in anaplastic lymphoma kinase (ALK)-resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells.
  • Alectinib is the active ingredient in AlecensaTM, an ALK inhibitor approved for the treatment of NSCLC.
  • Moreover, effective inhibition of signaling pathways associated with osimertinib and alectinib resistance were observed in the respective cell lines tested.

Avicanna Reports Full Year 2023 Audited Financial Results 

Retrieved on: 
Mardi, avril 2, 2024
Cream, Cannabidiol, Cannabinoid, Dravet syndrome, Brazilian Health Regulatory Agency, Interest, Medical cannabis, Seizure, Business, Lennox–Gastaut syndrome, Patient, Pharmacy, Active ingredient, Research, Acquisition, RDC, Ultra, Stock, CBD, Insurance, Health Canada, Bank statement, GMP, Dermatology, TSX, Therapy, Pharmaceutical industry

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce year end 2023 results and audited financial statements.

Key Points: 
  • TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce year end 2023 results and audited financial statements.
  • Cash used in operations of $1.38 million; an 81% reduction compared to $7.4 million in 2022.
  • “2023 was a tremendous year for Avicanna where we solidified of our leadership position in the Canadian medical cannabis sector through our proprietary products and the launch of MyMedi.ca.
  • We have successfully demonstrated the scalability of our revenues and made significant improvements in our fundamentals while advancing all our business pillars.

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Retrieved on: 
Lundi, avril 8, 2024
Biotechnology, Technology, Professional Services, Health, Pharmaceutical, Semiconductor, Research, Data Analytics, Software, Science, Hardware, Quality control, Evo, Corporation, NMR, Active ingredient, Bruker, AI, Ascend, PAT, API, Safety, Magnet, Hertz, Machine learning, Multimedia, Fourier, BRKR, Medical imaging

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug discovery, development and process analytical technologies (PAT).
  • The new Ascend Evo 600 magnet is easier to site, has reduced installation and operational costs, and has lower Helium consumption compared to previous 600 MHz magnets.
  • In addition, Bruker expands the applications of its Fourier 80 platform, a benchtop 80 MHz Fourier Transform NMR with a high-performance permanent magnet that requires no cryogens or power.
  • Here, the Fourier 80 system gathers reaction data for AI machine learning to formulate the rules and actions to guide process optimization.